Inclusion Criteria:

• Paroxysmal, persistent, permanent or long-term/longstanding persistent non-valvular AF and has not been diagnosed with rheumatic mitral valve disease
• CHA2DS2-VASc score of ≥ 3 for women and ≥ 2 for men
• Able to stop anticoagulation if the LAA is sealed
• Able to adhere to the protocol defined pharmacologic regimen following Amulet 2 device implant

Exclusion Criteria:

• Required to take P2Y12 platelet inhibitor beyond 6 months when Amulet 2 LAA Occluder implant procedure would occur
• Atrial septal defect or patent foramen ovale repair or occluder
• Implanted with a mechanical valve prosthesis or an inferior vena cava filter
• Left ventricular ejection fraction ≤30%
• Underwent prior attempted endocardial, epicardial, or surgical LAA closure or occlusion, defined as deployment of a device or surgical procedure whether successful or unsuccessful
• Underwent any cardiac or non-cardiac intervention or surgery within 30 days prior to Amulet 2 device implant attempt
• Experienced stroke or transient ischemic attack within 90 days prior to Amulet 2 device implant attempt
• Underwent catheter ablation for AF or atrial flutter within 60 days prior to Amulet 2 device implant attempt

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 10/11/2024. Questions regarding updates should be directed to the study team contact.